Payment overview · 2025
General Payments
$309.92
17 reported records · 10 companies
Healthcare provider profile · identity verified
Lene A Heinlen, DO
Allopathic & Osteopathic Physicians|Family Medicine · SAINT IGNACE, MI · NPI 1841267762
Verified facts
What the public records show
CMS Open Payments records show Lene A Heinlen, DO received $309.92 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.29 | 19.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.06 | 16.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.30 | 15.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $41.15 | 13.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.57 | 7.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.24 | 6.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.91 | 6.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.85 | 5.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.43 | 5.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.12 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.16 | 16 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.29 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.06 | 3 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $41.15 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 18 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 677 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 84 |
| Omeprazole | Omeprazole | 266 | 78 |
| Gabapentin | Gabapentin | 253 | 46 |
| Lisinopril | Lisinopril | 227 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 58 |
| Alprazolam | Alprazolam | 189 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 56 |
| Pregabalin | Pregabalin | 178 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 171 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 49 |
| Tramadol Hcl | Tramadol Hcl | 159 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 35 |
| Losartan Potassium | Losartan Potassium | 125 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 19 |
| Famotidine | Famotidine | 90 | 24 |
| Metformin Hcl | Metformin Hcl | 90 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 19 |
| Meloxicam | Meloxicam | 84 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 84 | suppressed |
| Diazepam | Diazepam | 82 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 21 |
| Sertraline Hcl | Sertraline Hcl | 78 | 20 |
| Eliquis | Apixaban | 75 | 18 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Ondansetron Odt | Ondansetron | 73 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 24 |
| Atenolol | Atenolol | 71 | 18 |
| Trazodone Hcl | Trazodone Hcl | 71 | 19 |
| Montelukast Sodium | Montelukast Sodium | 68 | 18 |
| Carvedilol | Carvedilol | 66 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 15 |
| Prednisone | Prednisone | 65 | 21 |
| Simvastatin | Simvastatin | 62 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 11 |
| Furosemide | Furosemide | 52 | 19 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | 14 |
| Methylprednisolone | Methylprednisolone | 51 | 31 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Topiramate | Topiramate | 49 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Methocarbamol | Methocarbamol | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 42 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 18 |
| Potassium Chloride | Potassium Chloride | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Cephalexin | Cephalexin | 30 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Nystatin | Nystatin | 29 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | 11 |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alosetron Hcl | Alosetron Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $309.92 · 17 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, EOHILIA, EVENITY, Korlym, LEQVIO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, VYEPTI, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error